The U.S. Food and Drug Administration (FDA) has approved Eli Lilly’s new oral weight loss pill, Foundayo, marking a pivotal moment in the rapidly evolving obesity treatment landscape. Announced on April 1, 2026, this approval places Lilly in direct competition with Novo Nordisk, whose Wegovy pill already entered the American market in late 2025. The rivalry between these pharmaceutical giants is set to reshape how millions of people manage obesity, offering alternatives to the injectable GLP-1 drugs that have dominated the field in recent years.
Foundayo, known scientifically as orforglipron, is the first small-molecule GLP-1 pill from Lilly. Unlike peptide-based injectables, which require cold storage and careful handling, Foundayo’s oral formulation promises to be more accessible and easier to distribute globally. Lilly CEO Dave Ricks told CNBC, “Here is an option that’s not more effective ... but it’s more accessible, it’s easier to fit into your daily routine.” According to Lilly, the once-daily pill can be taken at any time, without restrictions on food or water intake—a convenience that sets it apart from competitor Wegovy, which must be consumed first thing in the morning on an empty stomach with only a few ounces of water.
The FDA’s approval of Foundayo came through the agency’s commissioner’s voucher program, which fast-tracks review for drugs considered national health priorities. This was only the fifth medication approved via the National Priority Voucher pilot program. The approval was based on data from the ATTAIN-1 trial, in which patients on the highest dose of Foundayo lost an average of 27.3 pounds, or 12.4% of their body weight, compared to just 2.2 pounds (0.9%) for those on placebo.
Foundayo’s launch is scheduled for the week of April 6, 2026, with the drug becoming available through LillyDirect, at pharmacies, and via telehealth services. Pricing has been a focal point in the rollout. For those with insurance, a coupon from Lilly can reduce the cost to $25 per month, while out-of-pocket expenses range from $149 to $349 depending on the dose. Starting July 1, Medicare Part D beneficiaries will be able to access Foundayo for just $50 per month, thanks to a deal struck with the Trump administration last fall. This agreement also set the starting cash price for the lowest doses of both Foundayo and Wegovy at $149, leveling the playing field for cost-conscious consumers.
The competitive landscape is fierce. Novo Nordisk’s Wegovy pill, approved by the FDA in December 2025, has already seen strong uptake, with more than 600,000 prescriptions in March 2026 alone. A recent analysis revealed that 36% of new Wegovy pill users had never previously tried a GLP-1 therapy, suggesting that oral tablets are drawing in patients who may have been hesitant to start with injections. Novo Nordisk is keen to highlight its product’s advantages. In a statement, Jamey Millar, EVP of U.S. operations for Novo, said, “Not all GLP-1s are the same. Any reports claiming orforglipron is more effective than Wegovy pill for weight management are inaccurate and misleading. There is no head-to-head trial comparing the efficacy of orforglipron and Wegovy pill, and Wegovy pill has demonstrated a magnitude of weight loss no other oral GLP-1 obesity candidate by itself, as a singular molecule, has shown in a Phase 3 study without the benefit of another agent. Wegovy is also proven to reduce the risk of major adverse cardiovascular events such as death, heart attack, or stroke in adults with overweight or obesity and established CV disease. When it comes to weight loss medicines, only Wegovy can make this claim.”
Head-to-head comparisons are indeed tricky. In clinical trials, the Wegovy pill achieved about 16.6% weight loss on average, while Foundayo’s top dose resulted in roughly 12.4% weight loss among patients who remained on treatment. Injectable options like Lilly’s Zepbound have shown even greater efficacy, consistently helping people lose more than 20% of their body weight. Yet, as Dr. Nidhi Kansal of Northwestern Medicine points out, “Unfortunately, price is what is driving the decision-making between clinicians and patients for these drugs because they’re all excellent drugs and we have lots of options now, but it’s still a financial decision at the end of the day.”
Beyond efficacy and price, convenience is a major selling point. Foundayo’s lack of dosing restrictions could appeal to those who find the morning routine for Wegovy inconvenient. As BMO Capital Markets analyst Evan David Seigerman noted, the pill format and lower price point may open the market to “casually interested patients”—those who might not have considered weight loss medication before.
Lilly’s ambitions for Foundayo are global. The company expects to secure approval for the pill in more than 40 countries within the next year. Since 2020, Lilly has invested over $55 billion in manufacturing, including new sites and plant expansions, to support the worldwide rollout. “This will be marketed around the world. As soon as we have regulatory approvals, we essentially have as much scale as we need to supply the world with an oral GLP-1 inhibitor,” Ricks told CNBC. The company licensed orforglipron from Japanese drugmaker Chugai in 2018, paying $50 million upfront for global rights—a bet that appears to be paying off as analysts project Foundayo sales could reach $14.79 billion by 2030.
The road to approval wasn’t without controversy. The commissioner’s voucher program has drawn scrutiny, with some insiders suggesting it opens the door to political interference. Reports surfaced that Lilly pressed the FDA for a faster review, but a company spokesperson told Reuters they expected a thorough, science-based process. Regardless, the FDA granted the green light, and the market responded swiftly. Lilly’s stock, which had fallen about 14% earlier in 2026 after a meteoric rise that briefly crowned the company as the world’s first trillion-dollar healthcare firm, rebounded by 5% following the announcement.
Looking ahead, Lilly is not resting on its laurels. The company is anticipating results from late-stage trials for its next-generation obesity shot, retatrutide, which could further expand its portfolio and keep it at the forefront of obesity care. As Ricks put it, “The future will be more choices, and that’s a great thing. And we hope Lilly is the one presenting those choices.”
For now, the approval of Foundayo signals a new era of competition and innovation in obesity treatment—one where patients, providers, and insurers will weigh convenience, efficacy, price, and access as they navigate a growing menu of therapeutic options.